SCHEDULE 13G: Venrock Affiliates Disclose 9.9% Stake in Jade Biosciences, Inc. via Schedule 13G Filing

A group of Venrock Healthcare Capital Partners entities and individuals have disclosed a collective 9.9% beneficial ownership stake in Jade Biosciences, Inc., as detailed in a recent Schedule 13G filing.

Summary

• Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh (collectively, the "Reporting Persons") have filed a Schedule 13G.
• The Reporting Persons collectively beneficially own 3,220,369 shares of Common Stock of JADE BIOSCIENCES, INC., representing 9.9% of the class.
• This ownership includes common stock and Pre-Funded Warrants, which contain a "Beneficial Ownership Blocker" limiting exercise to prevent ownership exceeding 9.99% of the Issuer's outstanding common stock.
• The percentage of class is based on 32,235,926 shares of common stock outstanding as of April 28, 2025, plus 5 shares issuable upon exercise of the Pre-Funded Warrants, with the reported 9.9% being a rounding down from 9.99% due to EDGAR system limitations.
• The filing states that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely related to a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a Schedule 13G is a factual disclosure, the maintenance of a significant stake (9.9%) by a prominent institutional investor group like Venrock Healthcare Capital Partners generally signals continued confidence in the company, which is a positive indicator for other investors.

Positives

• The disclosure of a significant beneficial ownership stake by a reputable healthcare capital firm like Venrock may signal confidence in Jade Biosciences, Inc.'s long-term prospects.
• The continued holding of a substantial stake by this institutional group indicates ongoing interest in the company.

Risks

• The document does not explicitly detail operational, financial, or market risks specific to Jade Biosciences, Inc.
• The "Beneficial Ownership Blocker" within the Pre-Funded Warrants limits the Reporting Persons' ability to increase their beneficial ownership beyond 9.99%, which could restrict their potential for greater influence or investment in the company.

Future Outlook

The document is a regulatory disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Jade Biosciences, Inc.'s future performance or strategic plans.

Management Comments

• "The Reporting Persons are members of a group for the purposes of this Schedule 13G."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This Schedule 13G filing indicates a significant institutional investment in Jade Biosciences, Inc., a company operating within the biotechnology or life sciences sector. While the filing itself does not provide broader industry trends, it highlights continued investor interest in companies within this space.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant institutional investor's stake, which can influence market perception and potentially share price.
• Management: Awareness of a large, stable institutional shareholder group may influence strategic decisions or corporate governance considerations.

Next Steps

• The Reporting Persons will continue to comply with SEC filing requirements under the Securities Exchange Act of 1934, including any necessary amendments to Schedule 13G or other forms (e.g., Forms 3, 4, and 5) related to their holdings and transactions in Jade Biosciences, Inc. securities.

Key Dates

Keywords

Jade Biosciences Inc., Venrock Healthcare Capital Partners, Schedule 13G, Beneficial Ownership, Common Stock, Pre-Funded Warrants, Institutional Investor, SEC Filing, Shareholder Disclosure, Biotechnology